MKI67 and neoplasm: Despite this, the results consistently favor the experimental intervention, suggesting that it may contribute to improved outcomes, possibly related to tumor shrinkage or Ki-67 reduction. Clinically, this supports using tumor size reduction and possibly Ki-67 levels as biomarkers to assess NAC efficacy and predict pCR.